For the quarter ending 2025-09-30, GALT made $4,237K in revenue. -$8,223K in net income. Net profit margin of -194.08%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,611 | 3,261 | ||
| General and administrative | 1,587 | 1,364 | ||
| Total operating expenses | 4,198 | 4,625 | ||
| Total operating loss | -4,198 | -4,625 | ||
| Interest income | 39 | 26 | ||
| Interest expense | 1,820 | 1,826 | ||
| Change in fair value of derivative | -2,205 | -1,096 | ||
| Total other income (expense) | -3,986 | -2,896 | ||
| Net loss | -8,184 | -7,521 | ||
| Preferred stock dividends | 39 | 63 | ||
| Net loss applicable to common stockholders | -8,223 | -7,584 | ||
| Net loss per common share basic (in dollars per share) | -0.13 | -0.12 | ||
| Net loss per common share diluted (in dollars per share) | -0.13 | -0.12 | ||
| Weighted average common shares outstanding basic (in shares) | 64,205,000 | 63,447,000 | ||
| Weighted average common shares outstanding diluted (in shares) | 64,205,000 | 63,447,000 | ||
GALECTIN THERAPEUTICS INC (GALT)
GALECTIN THERAPEUTICS INC (GALT)